文献速递皮肤肿瘤

非经典EphA2信号驱动BRAF抑制剂耐药黑色素瘤的转移

Noncanonical EphA2 Signaling Is a Driver of Tumor-Endothelial Cell Interactions and Metastatic Dissemination in BRAF Inhibitor‒Resistant Melanoma.
PubMed 文献 · J Invest Dermatol · 2020-09-02

本研究探讨获得性BRAF/MAPK/ERK抑制剂耐药黑色素瘤中与转移风险相关的转录状态。研究发现非经典EphA2-S897E信号通过Cdc42激活诱导间质-阿米巴样转变,促进黑色素瘤细胞侵袭、剪切应力下存活、与内皮细胞黏附及跨内皮迁移,并在体内增强肺滞留;该耐药相关转移状态依赖组蛋白去乙酰化酶8活性。

要点

  • 非经典EphA2-S897E信号经Cdc42激活驱动间质-阿米巴样转变,促进黑色素瘤侵袭与跨内皮迁移。
  • 表达EphA2-S897E或活性Cdc42的黑色素瘤细胞在尾静脉注射后肺滞留更优。
  • 耐药相关转移状态依赖HDAC8活性,沉默HDAC8可抑制EphA2与Akt磷酸化并减少侵袭。

核心结论

  • 获得性BRAF抑制剂耐药相关的转移状态依赖非经典EphA2信号,导致黑色素瘤-内皮细胞相互作用增强和肿瘤播散增加。

研究设计与样本

  • 采用基于质谱的蛋白质组学和表型实验,在黑色素瘤细胞中研究非经典EphA2-S897E的作用。
  • 体内采用尾静脉注射模型观察黑色素瘤细胞的肺滞留。
  • 分析BRAF抑制剂敏感与耐药黑色素瘤细胞,比较间质-阿米巴样转变、Cdc42活性、侵袭和跨内皮迁移。

主要发现

  • 黑色素瘤细胞表达活性非经典EphA2-S897E导致由Cdc42激活驱动的间质-阿米巴样转变。
  • 间质-阿米巴样转变促进黑色素瘤细胞侵袭、剪切应力下存活、持续流条件下与内皮细胞黏附、增加内皮单层通透性并刺激跨内皮迁移。
  • 表达EphA2-S897E或活性Cdc42的黑色素瘤细胞在尾静脉注射后肺滞留更优。
  • BRAF抑制剂耐药与间质-阿米巴样转变转换、Cdc42活性上调、侵袭增加和跨内皮迁移增加相关。
  • 沉默HDAC8导致EphA2和蛋白激酶B磷酸化受抑、侵袭减少及黑色素瘤细胞-内皮细胞相互作用受损。

临床怎么用

  • 提示非经典EphA2-Cdc42轴及HDAC8可能作为BRAF抑制剂耐药黑色素瘤转移风险的干预靶点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acquired BRAF/MAPK/extracellular signal‒regulated kinase inhibitor resistance in melanoma results in a new transcriptional state associated with an increased risk of metastasis. In this study, we identified noncanonical ephrin receptor (Eph) EphA2 signaling as a driver of the resistance-associated metastatic state. We used mass spectrometry‒based proteomic and phenotypic assays to demonstrate that the expression of active noncanonical EphA2-S897E in melanoma cells led to a mesenchymal-to-amoeboid transition driven by Cdc42 activation. The induction of mesenchymal-to-amoeboid transition promoted melanoma cell invasion, survival under shear stress, adhesion to endothelial cells under continuous-flow conditions, increased permeability of endothelial cell monolayers, and stimulated melanoma transendothelial cell migration. In vivo, melanoma cells expressing EphA2-S897E or active Cdc42 showed superior lung retention after tail-vain injection. Analysis of BRAF inhibitor‒sensitive and ‒resistant melanoma cells demonstrated resistance to be associated with a mesenchymal-to-amoeboid transition switch, upregulation of Cdc42 activity, increased invasion, and transendothelial migration. The drug-resistant metastatic state was dependent on histone deacetylase 8 activity. Silencing of histone deacetylase 8 led to the inhibition of EphA2 and protein kinase B phosphorylation, reduced invasion, and impaired melanoma cell-endothelial cell interactions. In summary, we have demonstrated that the metastatic state associated with acquired BRAF inhibitor resistance is dependent on noncanonical EphA2 signaling, leading to increased melanoma-endothelial cell interactions and enhanced tumor dissemination.

来源:J Invest Dermatol,查看原文。版权归原作者所有。

引用

  1. Zhang C, Smalley I, Emmons MF, et al. Noncanonical EphA2 Signaling Is a Driver of Tumor-Endothelial Cell Interactions and Metastatic Dissemination in BRAF Inhibitor‒Resistant Melanoma. J Invest Dermatol. 2020. PMID: 32890629. doi:10.1016/j.jid.2020.08.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。